GLP-1-based therapies are slowly approaching #bariatricsurgery level #weightloss and more exciting science to come. There is the impressive SURMOUNT-1 trial for tirzepatide #obesity nejm.org/doi/full/10.10…
Among the compelling findings, 63% of subjects achieved > 20% #weightloss with 15 mg once weekly Tirzepatide over 72 weeks #obesity nejm.org/doi/full/10.10… 
The results obtained with semaglutide and now tirzepatide provide compelling examples of how investments in science over time enable new more effective therapies for metabolic disorders #T2D #Obesity perhaps #NASH. These results also raise the bar for new mechanisms in the space
In the @NEJM Editorial for SURMOUNT-1, it is stated that "GLP-1 ...also has direct effects on adipocytes, as well as cardiovascular tissue and bone." In my little world, GLP-1 does not have direct effects on adipocytes or bone 🕵️nejm.org/doi/full/10.10…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
